We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$5.2B
AUM Growth
-$978M
Cap. Flow
-$699M
Cap. Flow %
-13.46%
Top 10 Hldgs %
44.11%
Holding
176
New
13
Increased
49
Reduced
69
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.9M
2
BRKR icon
Bruker
BRKR
+$21.3M
3
AMGN icon
Amgen
AMGN
+$19M
4
EHC icon
Encompass Health
EHC
+$16.6M
5
THC icon
Tenet Healthcare
THC
+$15.6M

Top Sells

Rank Stock Value
1
OPCH icon
Option Care Health
OPCH
+$51.8M
2
EPIX
ESSA Pharma
EPIX
+$47.8M
3
EXAS
Exact Sciences
EXAS
+$47M
4
CDNA icon
CareDx
CDNA
+$43.1M
5
EXEL icon
Exelixis
EXEL
+$41.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Miscellaneous 0.08%
3 Industrials 0.04%
4 Communication Services 0.03%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
101
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$3.32M 0.06%
+5,660
New +$3.33M
SMMT icon
102
Summit Therapeutics
SMMT
$14B
$3.04M 0.06%
170,594
+106,500
+166% +$2.06M
BTSG icon
103
BrightSpring Health Services
BTSG
$12B
$2.97M 0.06%
+174,152
New +$3.01M
CAH icon
104
Cardinal Health
CAH
$57.5B
$2.64M 0.05%
22,298
-7,926
-26% -$925K
RXRX icon
105
Recursion Pharmaceuticals
RXRX
$1.95B
$2.55M 0.05%
377,806
-15,075
-4% -$101K
AZN icon
106
AstraZeneca
AZN
$252B
$2.34M 0.05%
17,850
+1,100
+7% +$154K
BMY icon
107
Bristol-Myers Squibb
BMY
$136B
$2.16M 0.04%
38,113
+1,288
+3% +$72K
ACCD
108
DELISTED
Accolade Inc
ACCD
$2.11M 0.04%
615,509
-25,356
-4% -$90.1K
ZTS icon
109
Zoetis
ZTS
$31.3B
$1.59M 0.03%
9,779
+4,495
+85% +$804K
RDY icon
110
Dr. Reddy's Laboratories
RDY
$9.97B
$1.55M 0.03%
97,900
-5,075
-5% -$76.2K
DOCS icon
111
Doximity
DOCS
$4.7B
$1.49M 0.03%
27,911
-1,149
-4% -$56.3K
TEVA icon
112
Teva Pharmaceuticals
TEVA
$42.4B
$1.34M 0.03%
60,598
-10,223
-14% -$186K
RYTM icon
113
Rhythm Pharmaceuticals
RYTM
$7.07B
$1.32M 0.03%
23,596
+7,896
+50% +$436K
GOOG icon
114
Alphabet (Google) Class C
GOOG
$4.1T
$1.14M 0.02%
6,000
– –
PCVX icon
115
Vaxcyte
PCVX
$9.1B
$985K 0.02%
12,038
+57
+0.5% +$5.66K
CERT icon
116
Certara
CERT
$1.21B
$981K 0.02%
92,129
-3,795
-4% -$41.2K
CVS icon
117
CVS Health
CVS
$124B
$981K 0.02%
21,844
-222
-1% -$12.5K
BNTX icon
118
BioNTech
BNTX
$26.1B
$949K 0.02%
8,332
-389
-4% -$44.4K
PTGX icon
119
Protagonist Therapeutics
PTGX
$9.43B
$916K 0.02%
23,718
+11,372
+92% +$496K
GDX icon
120
VanEck Gold Miners ETF
GDX
$30.7B
$888K 0.02%
+26,200
New +$1.01M
AMRX icon
121
Amneal Pharmaceuticals
AMRX
$6.07B
$795K 0.02%
100,414
+24,000
+31% +$201K
KRYS icon
122
Krystal Biotech
KRYS
$10.6B
$791K 0.02%
5,047
+268
+6% +$47.5K
NAMS icon
123
NewAmsterdam Pharma
NAMS
$3.04B
$643K 0.01%
25,000
+17,300
+225% +$367K
ARQT icon
124
Arcutis Biotherapeutics
ARQT
$3B
$550K 0.01%
39,500
– –
VKTX icon
125
Viking Therapeutics
VKTX
$4.07B
$521K 0.01%
12,939
-3,240
-20% -$185K
3 4
5
6 7

Similar funds

SP
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
NHC
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Bellevue Group's Q4 2024 Portfolio in Review

As of Q4 2024, Bellevue Group held 176 positions worth $5.2B, down 16% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Bellevue Group withdrew a net $699M in Q4 2024, closing 15 positions and reducing 69 holdings. Its most notable exit was Option Care Health, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Bellevue Group opened a new position in Bruker worth $21.1M.

  • Bellevue Group's largest Q4 2024 buy was Bruker: 359,588 shares worth $21.1M.
  • Bellevue Group added most to Merck in Q4 2024, an estimated $22.9M increase.
  • Bellevue Group's biggest Q4 2024 reduction was Exact Sciences, cutting an estimated $47M.
  • Bellevue Group fully exited Option Care Health in Q4 2024, selling an estimated $51.8M.
  • Bellevue Group's ten largest holdings make up 44% of its $5.2B portfolio in Q4 2024.
  • Bellevue Group opened 13 new positions and closed 15 in Q4 2024.
  • Bellevue Group's portfolio value fell 16% quarter-over-quarter to $5.2B.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.